{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:30:05Z","timestamp":1775266205807,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.clcc.2012.09.003","type":"journal-article","created":{"date-parts":[[2012,10,26]],"date-time":"2012-10-26T06:01:09Z","timestamp":1351231269000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Alternative Treatment Options in Colorectal Cancer Patients With 5\u2013Fluorouracil- or Capecitabine-Induced Cardiotoxicity"],"prefix":"10.1016","volume":"12","author":[{"given":"Guido","family":"Deboever","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Hiltrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Cool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2012.09.003_bib1","first-page":"3766","article-title":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: un updated analysis [published erratum appears in J Clin Oncol 2005;23:1377-8]","volume":"22","author":"Thirion","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","article-title":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.clcc.2012.09.003_bib3","first-page":"1","article-title":"Efficacy and safety of capecitabine for colorectal cancer","volume":"2","author":"Chu","year":"2003","journal-title":"Am J Oncol Rev"},{"key":"10.1016\/j.clcc.2012.09.003_bib4","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib6","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000227226","article-title":"Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study","volume":"50","author":"Akhtar","year":"1993","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2012.09.003_bib8","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.ejca.2005.03.027","article-title":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/030089168206800609","article-title":"Cardiac toxicity of 5-fluorouracil: a study on 1083 patients","volume":"68","author":"Labianca","year":"1982","journal-title":"Tumori"},{"key":"10.1016\/j.clcc.2012.09.003_bib10","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E","article-title":"Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer","volume":"72","author":"Sch\u00f6ber","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jjco\/hyi071","article-title":"Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up","volume":"35","author":"Meydan","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib12","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib14","first-page":"41","article-title":"Capecitabine-related cardiotoxicity: recognition and management","volume":"6","author":"Saif","year":"2008","journal-title":"J Support Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152506775268785","article-title":"Cardiotoxicity of 5-fluorouracil","volume":"4","author":"Alter","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.clcc.2012.09.003_bib16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C","article-title":"The syndrome of 5-fluorouracil cardiotoxicity","volume":"71","author":"Robben","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clcc.2012.09.003_bib18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-Fluorouracil induces arterial vasocontractions","volume":"15","author":"S\u00fcdhoff","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0002-8703(87)90517-5","article-title":"5-Fluorouracil-induced coronary vasospasm","volume":"114","author":"Burger","year":"1987","journal-title":"Am Heart J"},{"key":"10.1016\/j.clcc.2012.09.003_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1253\/jcj.59.303","article-title":"A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction","volume":"59","author":"Mizuno","year":"1995","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.clcc.2012.09.003_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clcc.2012.09.003_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clcc.2012.09.003_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1191\/0960327106ht628oa","article-title":"Cardiac lesions induced by 5-fluorouracil in the rabbit","volume":"25","author":"Tsibiribi","year":"2006","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.clcc.2012.09.003_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00000441-198710000-00004","article-title":"5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators","volume":"294","author":"Patel","year":"1987","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clcc.2012.09.003_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/bjc.1998.12","article-title":"The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate","volume":"77","author":"Arellano","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib26","series-title":"Handbook of Experimental Pharmacology","first-page":"387","article-title":"Monofluoro aliphatic compounds","author":"Patterson","year":"1966"},{"key":"10.1016\/j.clcc.2012.09.003_bib27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0021-5198(19)52945-6","article-title":"Cardiotoxic effects of 5-fluorouracil in the guinea pig","volume":"30","author":"Matsubara","year":"1980","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.clcc.2012.09.003_bib28","first-page":"821","article-title":"Bolus 5-fluorouracil as an alternative modality to infusion 5-fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity","volume":"23","author":"Shaib","year":"2009","journal-title":"In Vivo"},{"key":"10.1016\/j.clcc.2012.09.003_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1445-5994.2009.02144.x","article-title":"Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina","volume":"40","author":"Stewart","year":"2010","journal-title":"Intern Med J"},{"key":"10.1016\/j.clcc.2012.09.003_bib30","first-page":"55","article-title":"Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen","volume":"8","author":"Cerny","year":"2009","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib31","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/jps.2600730217","article-title":"Effect of coadministration of uracil on the toxicity of tegafur","volume":"73","author":"Yamamoto","year":"1984","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clcc.2012.09.003_bib33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/annonc\/mdg254","article-title":"A dose-escalating study of oral eniluracil\/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies","volume":"14","author":"Yip","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-003-0613-0","article-title":"Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule","volume":"52","author":"Guo","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clcc.2012.09.003_bib35","first-page":"43","article-title":"Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer","volume":"2","author":"Marsh","year":"2002","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib37","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2002.04.123","article-title":"Multicenter phase III study of uracil\/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"Douillard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib38","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2005.04.7498","article-title":"Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel project Protocol C-06","volume":"24","author":"Lembersky","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib39","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2004.05.017","article-title":"Comparison of the efficacy, toxicity and pharmacokinetics of a uracil\/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT\/LV","volume":"22","author":"Shirao","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib40","first-page":"2059","article-title":"Potential regional differences for the tolerability profiles of fluoropyrimidines","volume":"24","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000209334","article-title":"The role of UFT in metastatic colorectal cancer","volume":"76","author":"Bennouna","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2012.09.003_bib42","first-page":"2","article-title":"Vasospasm after chemotherapy with 5-fluorouracil [in Spanish]","volume":"18","author":"Sell\u00e9s","year":"2001","journal-title":"An Med Int"},{"key":"10.1016\/j.clcc.2012.09.003_bib43","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","article-title":"Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study)","volume":"11","author":"Muro","year":"2010","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1016\/j.clcc.2012.09.003_bib44","article-title":"A randomized phase III study of SOX (S-1\/oxaliplatin) versus COX (capecitabine\/oxaliplatin) in patients with advanced colorectal cancer","volume":"29","author":"Park","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/17425247.2012.652945","article-title":"S-1 as a core anticancer fluoropyrimidine agent","volume":"9","author":"Miura","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.clcc.2012.09.003_bib46","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/sj.bjc.6600781","article-title":"EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer","volume":"88","author":"Van den Brande","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-003-0617-9","article-title":"Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors","volume":"52","author":"Peters","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clcc.2012.09.003_bib48","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.bjc.6601224","article-title":"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil","volume":"89","author":"Yamada","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib49","first-page":"941","article-title":"Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients","volume":"4","author":"Reigner","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2012.09.003_bib50","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10147-005-0516-7","article-title":"5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine","volume":"10","author":"Muneoka","year":"2005","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib51","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00003495-199855030-00012","article-title":"Raltitrexed","volume":"55","author":"Gunasekara","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.clcc.2012.09.003_bib52","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.ejca.2008.07.002","article-title":"Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)","volume":"44","author":"Popov","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib53","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/oxfordjournals.annonc.a010800","article-title":"Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer","volume":"7","author":"Cunningham","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib54","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","article-title":"Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer","volume":"16","author":"Cocconi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib55","article-title":"Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5- FU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized multicenter, North American trial","author":"Pazdur","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib56","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(02)08514-8","article-title":"Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial","volume":"359","author":"Maughan","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.clcc.2012.09.003_bib57","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/00001813-199708002-00004","article-title":"Overview of the tolerability of \u2018Tomudex\u2019 (raltitrexed): collective clinical experience in advanced colorectal cancer","volume":"8","author":"Zalcberg","year":"1997","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.clcc.2012.09.003_bib58","first-page":"66","article-title":"The use of raltitrexed (Tomudex) in a patient with 5-FU induced myocardial ischaemia","volume":"11","author":"Nutting","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib59","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/bjc.1998.160","article-title":"Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-FU","volume":"77","author":"K\u00f6hne","year":"1998","journal-title":"Br J Cancer"},{"issue":"June 1 Supplement","key":"10.1016\/j.clcc.2012.09.003_bib60","article-title":"TOMOX compared to FOLFOX 4 as first-line treatment in patients with advanced colorectal cancer (ACRC): results of a multicenter randomised phase II trial","volume":"23","author":"Gravalos","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1023\/A:1011194712661","article-title":"Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine\/leucovorin-based chemotherapy","volume":"12","author":"Scheithauer","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib62","first-page":"1139","article-title":"Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma","volume":"24","author":"Laudani","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2012.09.003_bib63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/07357900701518388","article-title":"Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience","volume":"25","author":"Wilson","year":"2007","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clcc.2012.09.003_bib64","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/annonc\/mdf229","article-title":"Irinotecan and raltitrexed: an active combination in advanced colorectal cancer","volume":"13","author":"Carnaghi","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib65","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/sj.bjc.6601713","article-title":"Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study","volume":"90","author":"Feliu","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib66","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/sj.bjc.6602860","article-title":"Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer","volume":"93","author":"Feliu","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib67","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdg285","article-title":"Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer","volume":"14","author":"Aparicio","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib68","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2012.09.003_bib69","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","article-title":"Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer","volume":"21","author":"Fuchs","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib70","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/CAD.0b013e32833c57cf","article-title":"Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer","volume":"21","author":"Oostendorp","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clcc.2012.09.003_bib71","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.bjc.6602462","article-title":"Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study","volume":"92","author":"Van Cutsem","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2012.09.003_bib73","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib74","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/cncr.22831","article-title":"Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer","volume":"110","author":"Ashley","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib75","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2010.09.022","article-title":"Phase III trial of irinotecan plus infusional 5-fluorouracil\/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer","volume":"47","author":"Fischer von Weikersthal","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2012.09.003_bib76","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1200\/JCO.2008.17.1249","article-title":"Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma","volume":"26","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2012.09.003_bib77","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2012.09.003_bib78","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002812001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002812001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:01:55Z","timestamp":1761519715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002812001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1533002812001107"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2012.09.003","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative Treatment Options in Colorectal Cancer Patients With 5\u2013Fluorouracil- or Capecitabine-Induced Cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2012.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}